) --

Jazz Pharmaceuticals



) hit a new 52-week high Thursday as it traded at $30.15 compared with its previous 52-Week high of $30.08. Jazz is changing hands at $30.05 with 265,810 shares traded as of 11:26 a.m. ET. Average volume has been 754,600 shares over the past 30 days.

Jazz has a market cap of $1.2 billion and is part of the

health care

sector and


industry. Shares are up 49.6% year to date as of the close of trading on Wednesday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company has a P/E ratio of 35.4, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.

  • Practice your JAZZ trading strategies and win cash in our stock game.

TheStreet Ratings rates Jazz as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including premium valuation and generally poor debt management. You can view the full

Jazz Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center